Syncom Formulations (India) Ltd (SYNCOMF) — shareholding pattern, promoter holding, financials and share price
About Syncom Formulations (India) Ltd (SYNCOMF)
Syncom Formulations (India) Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as SYNCOMF and on the BSE under scrip code 524470. Its ISIN is INE312C01025.
Established in the year 1995, Syncom Formulations is a global pharmaceutical company that manufactures and markets a broad range of healthcare products. The company is a generic pharmaceutical player operating in more than 15 countries worldwide having more than 400 products registered. [1]
Syncom Formulations (India) Limited operates in the Indian Pharmaceutical Industry, manufacturing and marketing over 200 pharmaceutical formulations. The company specializes in tablets, capsules, liquids, injectables, and herbal products.
Syncom has strategically expanded its manufacturing capacity over the years, notably enhancing tablet and capsule production and establishing modern facilities in Pithampur and Palghar.
Listed peers in Pharmaceuticals: Shukra Pharmaceuticals Ltd, Fredun Pharmaceuticals Ltd, Lincoln Pharmaceuticals Ltd, Accent Microcell Ltd, Fermenta Biotech Ltd, Bajaj Healthcare Ltd.
Valuation & Returns
10 Jul 2026At ₹14.18 a share on 10 Jul 2026, Syncom Formulations (India) Ltd (SYNCOMF) was valued at a price-to-earnings ratio of 17.44x against an industry P/E of 36.41x and a price-to-book of 3.9x on a book value of ₹3.64 per share as of Mar 2025. Solomo computes return on equity of 22.34% and return on capital employed of 29.49% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 17.44x
- Industry P/E
- 36.41x
- P/B
- 3.9x
- EPS (TTM)
- ₹0.81
- Book value / share
- ₹3.64
- ROE
- 22.34%
- ROCE
- 29.49%
- ROA
- 18.49%
- Debt / equity
- 0.01x
- Dividend yield
- 0%
- EBITDA margin
- 22.24%
- 52-week range
- ₹10.21 – ₹19.4
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Syncom Formulations (India) Ltd (SYNCOMF) reported revenue of ₹489 crore, net profit of ₹76 crore and earnings per share of ₹0.81. That compares with revenue of ₹463 crore and net profit of ₹49 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹135 crore and net profit ₹25 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 216 | 222 | 262 | 463 | 489 |
| Net profit (₹ cr) | 20 | 20 | 25 | 49 | 76 |
| EPS (₹) | 0.23 | 0.21 | 0.27 | 0.53 | 0.81 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 10.69% | 17.63% | 28.20% | 76.55% |
| Profit growth | 18.82% | 27.95% | 35.17% | 95.30% |
| Stock price CAGR | 18% | 9% | 22% | -27% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 50.57% of Syncom Formulations (India) Ltd (SYNCOMF) (unchanged from the previous quarter), foreign institutional investors (FII) hold 0.35% and domestic institutional investors (DII) hold 0%. Market capitalisation was ₹1,333 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Dec 2002.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 50.57% | - | 0.35% | 0% | 49.43% |
| Mar 2026 | 50.57% | - | 0.21% | 0% | 49.43% |
| Dec 2025 | 50.57% | - | 0.26% | 0% | 49.43% |
| Sep 2025 | 50.57% | - | 0.1% | 0% | 49.43% |
| Jun 2025 | 50.57% | - | 0.41% | 0% | 49.43% |
| Mar 2025 | 50.57% | - | 0.11% | 0% | 49.43% |
| Dec 2024 | 50.57% | - | 0.13% | 0% | 49.43% |
| Sep 2024 | 50.57% | - | 0.1% | 0% | 49.43% |